title: [Treatment of inflammatory bowel disease].
abstract: Standard treatment for IBD with 5-ASA, steroids and immunosuppressants is rather effective and currently optimized using combinations of drugs or application routes. Among the biologics only infliximab has reached the therapeutic arsenal for Crohn's disease--it is as well effective in some patients with ulcerative colitis. Early aggressive treatment thus far is not established. Hormones and growth factors may play a role. Probiotics have a place in the treatment in particular for ulcerative colitis.
authors.affiliation: Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg. juergen.schoelmerich@klinik.uni-r.de
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000628:therapy*; D003424:Crohn Disease / Q000628:therapy*; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; D019804:Mesalamine; D011239:Prednisolone